HCW Biologics Inc.
No SEC Form 4 filings for $HCWB in the last 30 days.
See all $HCWB insider activity →HCW Biologics Inc. (HCWB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells Agreement includes pre-payment commitments for product sales and distribution of the s
Tenon Medical (TNON) shares rose 80% after-hours with no specific news, reporting Q2 revenue of $1.3M (up 127% YoY) and a net loss of $4.1M. BioVie (BIVI) gained 55% after positive Phase 2 trial results for its Parkinson's drug. Edesa Biotech (EDSA) advanced 7% after announcing Phase 2 trial preparations for vitiligo treatment. TransCode (RNAZ) and HCW Biologics (HCWB) also saw after-hours gains on trial updates.
HCW Biologics (HCWB) reported a wider Q2 net loss of $5.2 million versus $1.9 million a year earlier, with licensing revenue rising to $135,568 from $6,550. The company said there is substantial doubt about continuing as a going concern without additional funding. It expects Phase 1 data for HCW9302 in alopecia areata in Q4 2026.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning HCWB (HCW Biologics Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent HCWB coverage spans corporate actions, earnings and insider activity.
The partnership could expand market reach for HCW11‑006, potentially boosting revenue and stock valuation.
Early clinical signals plus FDA regulatory engagement can support a positive re-rating, especially for small-cap biotech momentum.
Going-concern language plus wider losses increases near-term financing and dilution risk, while Phase 1 readout timing offers a potential catalyst.
Clinical-stage readout and ongoing dosing for HCW9302 can shift perceived probability of success and near-term financing needs.
A small open-market insider buy is a mild positive signal, but it is not large enough to materially change near-term fundamentals.
AlphAI scores every news story that mentions HCWB with an AI model for sentiment and relevance, and aggregates insider trades from HCW Biologics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
HCW Biologics Inc. (HCWB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells Agreement includes pre-payment commitments for product sales and distribution of the s
2 min readTenon Medical (TNON) shares rose 80% after-hours with no specific news, reporting Q2 revenue of $1.3M (up 127% YoY) and a net loss of $4.1M. BioVie (BIVI) gained 55% after positive Phase 2 trial results for its Parkinson's drug. Edesa Biotech (EDSA) advanced 7% after announcing Phase 2 trial preparations for vitiligo treatment. TransCode (RNAZ) and HCW Biologics (HCWB) also saw after-hours gains on trial updates.
6 min readHCW Biologics (HCWB) reported a wider Q2 net loss of $5.2 million versus $1.9 million a year earlier, with licensing revenue rising to $135,568 from $6,550. The company said there is substantial doubt about continuing as a going concern without additional funding. It expects Phase 1 data for HCW9302 in alopecia areata in Q4 2026.
3 min readHCW Biologics Inc. (HCWB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results Miramar, FL – August 14, 2026 – HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on de
6 min readWong Hing C (Chief Executive Officer) purchased 23,210 shares of HCW Biologics Inc. (HCWB) at $2.58 on 2026-07-29.
2 min readFlowers Lee (SVP of Business Development) purchased 7,736 shares of HCW Biologics Inc. (HCWB) at $2.58 on 2026-07-29.
1 min readHCW Biologics Inc. (HCWB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering MIRAMAR, Fla., July 29, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative
6 min readHCW Biologics Inc. (NASDAQ: HCWB) priced a $1.6 million private placement, issuing 618,682 units at $2.585 per unit. Each unit includes one common share (or a pre-funded warrant) and a common warrant, subject to stockholder approval. Net proceeds will fund clinical trials for HCW9302 and IND-enabling work for HCW11-018b and HCW11-040.
3 min readHCW Biologics Inc. (HCWB) said its board approved a 1-for-6 reverse stock split effective before the open on June 30, 2026, after Nasdaq Hearings Panel requirements. The company expects shares to trade on a split-adjusted basis under the same ticker. Outstanding shares will fall from 9.58 million to about 1.60 million; no fractional shares will be issued. HCWB was $1.05, down 6.25%.
2 min readHCW Biologics Inc. (HCWB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001828673 0001828673 2026-06-15 2026-06-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min read
